CRGX•benzinga•
CARGO Therapeutics Reports 71 Patients Dosed In Phase 2 Firicabtagene Autoleucel Study; Interim Results Expected H1'25; FDA Clears IND For CRG-023, Phase 1 Enrollment Mid-2025; Announces Novel Allogeneic Platform For CAR T-Cell Therapy
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 10, 2025 by benzinga